These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2210155)

  • 1. In vivo models of arterial thrombosis and thrombolysis.
    Bush LR; Shebuski RJ
    FASEB J; 1990 Oct; 4(13):3087-98. PubMed ID: 2210155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging antithrombotic treatments for acute coronary syndromes.
    Golino P; Ragni M; Cirillo P; Buono C; Piro O; Chiariello M
    Cardiologia; 1999 Nov; 44(11):969-80. PubMed ID: 10686772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current concepts in coronary thrombolysis.
    Eisenberg PR
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1161-70. PubMed ID: 1400079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U; Dörge L; Fischer S
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of coronary thrombolysis and reocclusion.
    Becker R
    Clin Cardiol; 1997 Nov; 20(11 Suppl 3):III2-5. PubMed ID: 9422855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
    Fitzgerald DJ; Hanson M; FitzGerald GA
    J Clin Invest; 1991 Nov; 88(5):1589-95. PubMed ID: 1939647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antithrombin therapy in acute coronary syndromes].
    Maseri A; Andreotti F; Biasucci LM; Rebuzzi AG
    Cardiologia; 1994 Dec; 39(12 Suppl 1):7-13. PubMed ID: 7634317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
    Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single-Chain Antibody Specific for Activated GPIIb/IIIa.
    Bonnard T; Tennant Z; Niego B; Kanojia R; Alt K; Jagdale S; Law LS; Rigby S; Medcalf RL; Peter K; Hagemeyer CE
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28159824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of reocclusion after coronary thrombolysis.
    Eisenberg PR
    Z Kardiol; 1993; 82 Suppl 2():175-8. PubMed ID: 8328198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Coronary thrombosis--an old concept in a new light].
    Baur HR
    Schweiz Rundsch Med Prax; 1992 Sep; 81(39):1147-51. PubMed ID: 1410998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current perspectives in the treatment of thrombotic disorders.
    Drouet L; Caen JP
    Semin Thromb Hemost; 1989 Apr; 15(2):111-22. PubMed ID: 2665082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of adenosine on thrombosis and thrombolysis in a canine experimental preparation.
    Huang J; Feldbaum VM; Lucchesi BR; Werns SW
    Pharmacology; 2001; 63(3):166-74. PubMed ID: 11598423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis.
    Leopold JA; Loscalzo J
    Coron Artery Dis; 1995 Dec; 6(12):923-9. PubMed ID: 8723013
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
    Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.